Topic: Scott Gottlieb

Former FDA Commissioner Dr. Scott Gottlieb discussed the Hantavirus outbreak on a cruise ship, noting a two-to-six-week incubation period. He disagreed with other experts by suggesting a longer window of observation is needed to determine if additional cases will emerge from the initial exposure.

The hosts discuss the potential use of Ivermectin for Hantavirus, noting it is an RNA virus. Dr. Scott Gottlieb dismissed the treatment on television, arguing the drug's mechanism does not work against this specific virus, while the hosts point out that 15 different Hantavirus vaccines are currently in development by various military and health agencies.

The FDA is reportedly facing significant internal upheaval, with a loss of nearly half of its medical reviewers in key divisions like oncology and hematology. Dr. Scott Gottlieb noted that the departure of career experts and the influx of political appointees are damaging the agency's ability to regulate 20% of the US economy effectively.

The FDA is launching a crackdown on flavored e-cigarettes following a 75% increase in teen vaping over the last year. Commissioner Scott Gottlieb is considering banning flavors like mango and cucumber that appeal to minors. The hosts argue that these regulations are a precursor to heavy taxation and express skepticism about the long-term health effects of "dabbing" and vaping.

Former FDA Commissioner Scott Gottlieb, who serves on the board of Pfizer, expressed alarm over the CDC's decision to delay the Hepatitis B dose. He argued that the advisory committee (ACIP) is being degraded by "anti-vax activists" and that its decisions will no longer be respected by states or insurers. Gottlieb emphasized the risks of chronic infection in children under five, while the hosts suggest the shift is a necessary move toward informed consent and removing pharma indemnification.

Former FDA Commissioner and current Pfizer board member Scott Gottlieb defended direct-to-consumer pharmaceutical advertising on CNBC. Gottlieb argued that TV ads drive "help-seeking behavior" and lead to more diagnoses. The hosts criticize the "wishy-washy" questioning by Andrew Ross Sorkin regarding the ethics of drug commercials.

Former FDA Commissioner and current Pfizer board member Scott Gottlieb accidentally referred to the COVID-19 vaccine as "experimental" during a CNBC interview. He discussed the timeline for full FDA approval, suggesting it would provide employers with the impetus to mandate vaccinations. The hosts highlight the slip of the tongue as a rare admission of the vaccine's current status.

An interim FTC report alleges that PBMs aggressively steer patients toward high-cost specialty drugs and preferred pharmacies to maximize profits. For example, a generic leukemia drug costing $66 was reimbursed at $2,700. Former FDA Commissioner Scott Gottlieb explains how the "back-ended rebate" system allows PBMs and insurers to profit while patients pay high out-of-pocket costs at the pharmacy counter.

Former FDA Commissioner Scott Gottlieb discusses the implications of the Supreme Court overturning the Chevron doctrine. He suggests that while fact-based scientific decisions may remain stable, the agency will face increased litigation when attempting to regulate new technologies or flavored tobacco products without explicit Congressional mandates.

Former FDA Commissioner Scott Gottlieb notes a tension between federal health agencies and state agricultural regulators, who have been reluctant to allow inspectors onto farms. Testing milk is described as a "backdoor" way for the CDC and FDA to identify outbreaks on farms where they lack direct access, similar to previous strategies used during E. coli outbreaks in romaine lettuce.

Former FDA Commissioner Scott Gottlieb discusses the massive ransomware attack on Change Healthcare, a subsidiary of UnitedHealthcare. The attack disrupted a third of the U.S. medical claims system, highlighting a single point of failure in the healthcare infrastructure and prompting warnings about a potential "cyber pandemic."

Former FDA Commissioner Scott Gottlieb discussed the potential for Medicare to cover GLP-1 weight loss drugs like Wegovy and Ozempic. While current law prohibits Medicare from covering drugs solely for weight loss, new clinical data suggests these medications provide significant cardiovascular benefits, which would trigger mandatory coverage. This shift could result in a massive financial boon for pharmaceutical companies as millions of seniors become eligible.

The transition of COVID-19 vaccine distribution from the federal government to the private sector has resulted in widespread insurance billing "glitches." While officials like Dr. Scott Gottlieb and Dr. Celine Gounder maintain that vaccines should remain free for the insured, many patients are facing denials at pharmacies. Authorities expect these administrative issues to be resolved by mid-October.

Former FDA Commissioner and Pfizer board member Dr. Scott Gottlieb appeared on CBS to discuss the "highly mutated" BA.2.86 variant. Gottlieb noted that while the variant is genetically distinct, it does not yet appear more pathogenic. He promoted the mid-September rollout of new boosters, which will be funded by the Biden administration's $5 billion "Project Next Gen." The vaccines are expected to be available for free at pharmacies and health departments by Halloween.

Former FDA Commissioner Scott Gottlieb's involvement with Biobot and Alumina is highlighted in relation to the push for wastewater monitoring and PCR assay production. Media reports from CBS News suggest that while boosters will be available in September, a federal program will provide them for free starting in mid-October. The lack of media discussion regarding alternative treatments like Ivermectin is noted as a significant omission in public health reporting.

Former FDA Commissioner Scott Gottlieb discusses the "Eris" (EG.5) variant on CNBC, noting its ability to escape prior immunity while remaining less pathogenic than previous strains. Gottlieb emphasizes the importance of wastewater data from BioBot Analytics due to the unreliability of home testing and state reporting. The hosts criticize Gottlieb's ties to Pfizer and the potential for wastewater surveillance to be used for social control.

Scott Gottlieb provides conflicting statements on whether wastewater data is a forward-looking or backward-looking indicator for COVID-19 spikes. The hosts argue that the promotion of wastewater testing is a strategy to justify localized lockdowns and the widespread use of mail-in ballots in "red states." They suggest that surveillance of "pee water" will be used to restrict movement based on infection levels in specific residential quadrants.

Robert Kennedy Jr. claims Donald Trump was co-opted by the pharmaceutical industry early in his presidency. After Trump initially asked Kennedy to lead a vaccine safety commission, Pfizer reportedly donated $1 million to the inauguration. Subsequently, Trump appointed Pfizer lobbyists Scott Gottlieb and Alex Azar to lead HHS, effectively killing the commission. Gottlieb later joined the board of directors at Pfizer.

Scott Gottlieb appeared on Face the Nation with Margaret Brennan, drawing criticism for his alleged role in working with social media companies to ban users. Alex Berenson is reportedly threatening litigation against Gottlieb, though Gottlieb claimed on another program that he could not discuss the matter due to pending litigation. The hosts characterize Gottlieb as a "phony" and criticize the news program for failing to ask difficult questions about these controversies.

Subpoenaed records revealed that Pfizer board member Scott Gottlieb pressured Twitter executives to censor journalist Alex Berenson. Berenson, who previously won a lawsuit against Twitter for his reinstatement, documented how Gottlieb flagged specific tweets that questioned the efficacy of vaccines. This interaction highlights the direct influence of pharmaceutical interests on social media moderation policies.